Ro Khanna × PFE

This January 2025 buy is a minimum-bracket transaction at $1,001, the floor disclosure tier under STOCK Act reporting. It was filed on February 6, just 15 days after the trade date, placing it well within the statutory window. No peer clustering is present, and the size registers at exactly the median for this politician-ticker history, suggesting a routine incremental position addition consistent with the trust's broader pattern of frequent small-lot activity in Pfizer across 150 total disclosed trades. The committee overlap signal fires because Khanna's Armed Services and Oversight assignments provide indirect institutional exposure to Pfizer's federal contracting business, but nothing about this individual trade stands out beyond that structural context. Taken in isolation, this transaction carries a low aggregate signal density.

This April 9, 2025 sell is the highest-signal trade in the recent dataset for this politician-ticker pairing. Three distinct signals fire simultaneously: the $15,001 size is roughly 15 times the median transaction for this account's Pfizer history; the disclosure arrived 33 days after the trade, clearing the late-filing threshold by three days; and five members of Congress disclosed Pfizer trades within the same 14-day window, meeting the member-clustering criterion. The combination of an outsized sell, a slight disclosure delay, and broad peer-level activity in the same stock within the same narrow window is the type of pattern that warrants attention across the full 150-trade disclosure record. Khanna's committee assignments on Oversight and Armed Services provide institutional proximity to Pfizer's federal contracting exposure. No single signal here implies coordination, but the convergence of all three quantitative flags in one event is the most notable data point in this ten-trade sample.

This April 15, 2025 sell closely follows the April 9 sell in trade #7651, and together they represent a two-tranche exit from a Pfizer position within a six-day span. The $15,001 size again registers at roughly 15 times the median for this pair, and four members of Congress disclosed Pfizer trades in the surrounding 14-day window. The disclosure delay of 27 days narrowly avoids the late-filing flag, and both trades were ultimately disclosed on the same filing date of May 12, suggesting the filer batched them together. Across the 150 total Pfizer disclosures in this record, the pairing of back-to-back outsized sells with concurrent peer-level activity in the same stock represents a pattern distinct from the routine minimum-bracket transactions that dominate the broader history. Committee overlap remains a structural background factor given Khanna's Oversight assignment.

This May 19, 2025 buy at $15,001 arrives roughly five weeks after the pair of outsized sells in April, suggesting the trust may have been tactically repositioning rather than exiting Pfizer entirely. The size again clears the unusually-large threshold at approximately 15 times the median, and three members disclosed Pfizer trades in the same 14-day window, meeting the clustering threshold at its minimum. The disclosure was timely at 22 days. Across the broader 150-trade disclosure record, the oscillation between $1,001-bracket trades and $15,001-bracket trades appears to be a recurring structural feature of the account's Pfizer activity rather than an isolated event. The committee overlap signal fires at the background level given Khanna's Oversight and Armed Services roles, though neither committee directly sets pharmaceutical pricing or approval policy. The clustering signal at the threshold boundary is the most notable feature of this specific trade.

This May 28, 2025 buy at $1,001 is a minimum-bracket transaction filed promptly at 13 days. It follows the larger $15,001 buy on May 19 by just nine days, suggesting the trust continued adding to its Pfizer position in small increments after the initial re-entry. The size is unremarkable, matching the median exactly, and the filing delay is among the shortest in this ten-trade sample. The member-clustering signal fires at threshold because three members disclosed Pfizer trades in the surrounding 14-day window, which overlaps with the clustering period from the May 19 trade. This transaction on its own carries limited standalone signal, but in the context of the broader 150-trade history and the adjacent larger trades, it reads as part of a recurring pattern of incremental accumulation following a larger position-opening event. Committee overlap remains a structural background factor.

This June 20, 2025 buy at $1,001 is the third consecutive minimum-bracket Pfizer purchase in the recent sequence, following the May 19 and May 28 buys. The filing arrived 19 days after the trade, no clustering is present, and the size is at the median. Taken individually, this transaction has a low aggregate signal score. Within the context of the 150-trade disclosure record, however, this trade is representative of the dominant transaction type: small-lot incremental buys that collectively build or maintain a Pfizer position alongside occasional larger-bracket events. The committee overlap signal fires at the background level given Khanna's assignments, but no individual committee he serves on has direct authority over pharmaceutical pricing, approval, or the specific regulatory levers most material to Pfizer's near-term valuation. This trade contributes to pattern recognition across the full dataset rather than standing out on its own merits.

This July 1, 2025 buy at $1,001 was filed on August 7, producing a 37-day disclosure delay that exceeds the statutory 30-day threshold by one week. The trade size and peer-clustering metrics are unremarkable. Late filing on a minimum-bracket trade is the only flag here, and this is the first of two consecutive late disclosures in the recent record (the August 4 trade also arrived late). Batching or administrative lag in the trust's reporting process may explain the pattern, as both trades were filed approximately five weeks after execution. Across the 150-trade history, this filing behaviour warrants note: late disclosure of small-lot trades does not raise the same analytical concern as late disclosure of large-bracket trades, but recurring late filings are a STOCK Act compliance matter independent of trade size. Committee overlap remains a structural background signal.

This August 4, 2025 buy at $1,001 is the second consecutive late-disclosed Pfizer trade, arriving on September 9 after a 36-day gap. Together with the July 1 trade filed on August 7, the two late filings suggest a reporting lag in the trust's administrative process during the summer of 2025 rather than a strategic disclosure pattern. No clustering or size anomaly is present. Looking across the 150-trade disclosure history, isolated late filings occur periodically, but consecutive late filings on successive transactions may indicate a procedural gap in the trust's compliance workflow. The late disclosure signal is the sole quantitative flag for this trade. Committee overlap fires at the background level, as it does consistently across this politician-ticker pairing, given Khanna's assignments on panels with indirect exposure to Pfizer's federal business. No other signals are elevated.

This September 5, 2025 sell at $1,001 was filed on October 3, a 28-day delay that narrowly falls within the 30-day window. It is the first sell in the dataset since the April pair, suggesting the trust may be reducing its Pfizer position in small increments after several months of incremental buying. At the minimum bracket, no size or clustering signals fire. Across the 150-trade history, minimum-bracket sells are common and typically indicate position trimming or portfolio rebalancing at the floor disclosure tier rather than a material directional decision. The October 3 filing date is shared with the September 15 sell that follows in the record, indicating the filer again batched two consecutive transactions into a single filing event. Committee overlap fires at the structural background level as established across this pairing.

This September 15, 2025 sell at $1,001 was filed on October 3, 18 days after execution, and is the most recent transaction in this ten-trade sample. It follows the September 5 sell by ten days and was batched with that trade in a single filing, a practice observed repeatedly across this record. Both September sells are minimum-bracket transactions with no clustering or size flags. The pair appears to represent continued incremental position reduction following the summer accumulation sequence. Across 150 total disclosed trades in Pfizer, the recurring rhythm of small-lot buys followed by small-lot sells, punctuated by occasional $15,001-bracket events that coincide with broader peer clustering, is the defining structural characteristic of this account's relationship with the stock. The committee overlap signal fires consistently as a background condition given Khanna's institutional role, rather than as a trade-specific flag on this particular transaction.